Tech Company Financing Transactions
Alphyn Biologics Funding Round
Alphyn Biologics closed a $3.3 million Series A funding round on 9/19/2022. Investors included Queen City Angels, Angel Physicians Fund and Serial Stage Venture Partners.
Transaction Overview
Company Name
Announced On
9/19/2022
Transaction Type
Venture Equity
Amount
$3,300,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to conduct the Phase2a clinical trial of AB-101a, its lead candidate for the treatment of mild-to-moderate atopic dermatitis (AD), the most common form of eczema.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
3724 Thomas Point Road
Annapolis, MD Undisclosed
USA
Annapolis, MD Undisclosed
USA
Phone
Website
Email Address
Overview
Alphyn is using its patent pending AB-101 platform biomaterial to target the most difficult, severe and prevalent skin diseases facing humankind. AB-101's first target disease is Atopic Dermatitis (or AD, also known as Eczema). AD is difficult to treat, can be very severe for many people and affects millions of people worldwide. A solution for AD is clearly needed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neal Koller
Chief Scientific Officer
Gary Pekoe
President
Steven Pentelnik
Browse more venture capital transactions:
Prev: 9/19/2022: 1MRobotics venture capital transaction
Next: 9/19/2022: Portabl venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs